Drug delivery based on chitosan, β-cyclodextrin and sodium carboxymethyl cellulose as well as nanocarriers for advanced leukemia treatment - 31/08/22
, Mojgan Ghanbari d, Makarim A. Mahdi e, Waleed K. Abdulsahib f, Masoud Salavati-Niasari d, ⁎ 
Abstract |
Medicine/nanotechnology as a new and applicable technique according to drug delivery systems has gained great consideration for cancer treatment. Polysaccharides including, cellulose, β-cyclodextrin and sodium carboxymethyl cellulose and chitosan as natural bio-materials, are appropriate candidates for designing and formulations of these nanosystems because of the exceptional advantages such as bio-compatibility, bio-degradability, non-toxicity, and gelling characteristics. An intelligent drug delivery platform based on these hybrids nowadays is developed, which can be used for dual-responsive dual-drug delivery. Nanotechnology accompany with biological molecules has been carefully considered to decrease the drawbacks of conventional cancer treatments. Consequently, this review is intended to state and investigate on the latest development on the combination treatment of platforms based on the hybrids of anticancer drugs/nanoparticles/Polysaccharides in the fields of biomedical therapeutics and cancer therapy owing to the bio-compatibility, great surface area, good chemical and mechanical features, the challenges and future perspectives are reported as well.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The review designed to report the recent progress on therapy using NPs and anticancer drugs. |
• | This review describes the latest developments about Upconversion Nanocarriers in cancer treatment. |
• | This paper emphasizes different types of nanocarriers used in the cancer treatment. |
• | This work also enlightens drug delivery of anti-blood cancer drugs. |
Keywords : Leukemia, Nanocarriers, Nanostructures, Targeting drug release, Biopolymer: chitosan, cellulose, β-cyclodextrin, Biocompatible
Plan
Vol 153
Article 113369- septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
